Download PDF
Thromb Haemost 2008; 100(01): 154-155
DOI: 10.1160/TH08-01-0048
Case Report
Schattauer GmbH

Treatment of midgestational placental haemorrhage with recombinant factor VIIa

Alexander Krafft
1   Clinic of Obstetrics, Department of Obstetrics and Gynaecology, University Hospital Zurich, Zurich, Switzerland
,
Lars M. Asmis
2   Department of Haematology, University Hospital Zurich, Zurich, Switzerland
,
Roland Zimmermann
1   Clinic of Obstetrics, Department of Obstetrics and Gynaecology, University Hospital Zurich, Zurich, Switzerland
› Author Affiliations
Further Information

Publication History

Received 23 January 2008

Accepted after minor revision 07 May 2008

Publication Date:
22 November 2017 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Singh J, Fanaroff J, Andrews B. et al. Resuscitation in the “gray zone” of viability: determining physician preferences and predicting infant outcomes. Pediatrics 2007; 120: 519-526.
    CrossrefPubMedGoogle Scholar
  • 2 Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17 (Suppl. 01) S1-5.
    CrossrefPubMedGoogle Scholar
  • 3 Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. Br J Obstet Gyn 2007; 114: 8-15.
    PubMedGoogle Scholar
  • 4 O'Connell KA, Wood JJ, Wise RP. et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. J Am Med Assoc 2006; 295: 293-298.
    CrossrefPubMedGoogle Scholar
  • 5 Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost. 2005; 93: 1027-1035.
    PubMedGoogle Scholar
  • 6 Stanworth S, Birchall J, Doree C. et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database System Rev. 2007 02. Art. No.: CD005011. doi: 10.1002/14651858.CD005011.pub2.
    PubMedGoogle Scholar
  • 7 Ranucci M, Isgro G, Soro G. et al. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg 2008; 143: 296-304.
    CrossrefPubMedGoogle Scholar
  • 8 Martinelli I. Thromboembolism in women. Semin Thromb Hemost 2006; 32: 709-715.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Pabinger I, Grafenhofer H. Thrombosis during pregnancy: risk factors, diagnosis and treatment. Pathophysiol Haemost Thromb 2002; 32: 322-324.
    CrossrefPubMedGoogle Scholar
  • 10 Malek A, Sager R, Eckardt KU. et al. Lack of transport of erythropoietin across the human placenta as studied by an in vitro perfusion system. Pflugers Arch 1994; 427: 157-161.
    CrossrefPubMedGoogle Scholar
  • 11 Cade JF, Hirsh J, Martin M. Placental barrier to coagulation factors: its relevance to the coagualtion defect at birth and to haemorrhage in the newborn. Br Med J 1969; 02: 281-283.
    CrossrefPubMedGoogle Scholar
  • 12 Goldenberg RL, Culhane JF, Iams JD. et al. Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84.
    CrossrefPubMedGoogle Scholar
  • 13 Fanaroff AA, Stoll BJ, Wright LL. et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007 196. 147 e1-8.
    PubMedGoogle Scholar